Results of a randomized, prospective clinical trial evaluating metronomic chemotherapy in nonmetastatic patients with high‐grade, operable osteosarcomas of the extremities: A report from the Latin American Group of Osteosarcoma Treatment

Metronomic chemotherapy (MC) consists of the administration of a low dose of chemotherapy on a daily or weekly basis without a long break to achieve an antitumoral effect through an antiangiogenic effect or stimulation of the immune system. The potential effect of MC with continuous oral cyclophosphamide and methotrexate in patients with high‐grade operable osteosarcomas (OSTs) of the extremities was investigated.

[1]  B. Clarisse,et al.  Oral antineoplastic agents: how do we care about adherence? , 2015, British journal of clinical pharmacology.

[2]  M. Relling,et al.  Systemic Exposure to Thiopurines and Risk of Relapse in Children With Acute Lymphoblastic Leukemia: A Children's Oncology Group Study. , 2015, JAMA oncology.

[3]  M. Sydes,et al.  Methotrexate, Doxorubicin, and Cisplatin (MAP) Plus Maintenance Pegylated Interferon Alfa-2b Versus MAP Alone in Patients With Resectable High-Grade Osteosarcoma and Good Histologic Response to Preoperative MAP: First Results of the EURAMOS-1 Good Response Randomized Controlled Trial , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  C. Punt,et al.  Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group , 2015, The Lancet.

[5]  N. André,et al.  Maintenance chemotherapy in children with ALL exerts metronomic-like thrombospondin-1 associated anti-endothelial effect , 2015, Oncotarget.

[6]  K. S. Hall,et al.  EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment† , 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Michalis Mastri,et al.  Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy , 2014, EMBO molecular medicine.

[8]  N. André,et al.  Metronomics: towards personalized chemotherapy? , 2014, Nature Reviews Clinical Oncology.

[9]  D. Pieper,et al.  Adherence influencing factors in patients taking oral anticancer agents: a systematic review. , 2014, Cancer epidemiology.

[10]  I. Lewis,et al.  Osteosarcoma treatment - where do we stand? A state of the art review. , 2014, Cancer treatment reviews.

[11]  N. André,et al.  Metronomics as Maintenance Treatment in Oncology: Time for Chemo-Switch , 2014, Front. Oncol..

[12]  N. André,et al.  Preliminary evaluation of children treated with metronomic chemotherapy and valproic acid in a low-income country: Metro-Mali-02. , 2013, Indian journal of cancer.

[13]  S. Baruchel,et al.  A pilot study of low‐dose anti‐angiogenic chemotherapy in combination with standard multiagent chemotherapy for patients with newly diagnosed metastatic Ewing sarcoma family of tumors: A Children's Oncology Group (COG) Phase II study NCT00061893 , 2013, Pediatric blood & cancer.

[14]  M. Kieran,et al.  Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors , 2012, Pediatric blood & cancer.

[15]  N. André,et al.  Pilot study of a pediatric metronomic 4-drug regimen , 2011, Oncotarget.

[16]  S. Groshen,et al.  A phase I study of zoledronic acid and low‐dose cyclophosphamide in recurrent/refractory neuroblastoma: A new approaches to neuroblastoma therapy (NANT) study , 2011, Pediatric blood & cancer.

[17]  Jeffrey C. Allen,et al.  A phase II study of metronomic oral topotecan for recurrent childhood brain tumors , 2011, Pediatric blood & cancer.

[18]  Nicolas André,et al.  Metronomic chemotherapy: new rationale for new directions , 2010, Nature Reviews Clinical Oncology.

[19]  L. Mirabello,et al.  Osteosarcoma incidence and survival rates from 1973 to 2004 , 2009, Cancer.

[20]  Arin M. Connell.  Employing Complier Average Causal Effect Analytic Methods to Examine Effects of Randomized Encouragement Trials , 2009, The American journal of drug and alcohol abuse.

[21]  M. Sydes,et al.  International collaboration is feasible in trials for rare conditions: the EURAMOS experience. , 2007, Cancer treatment and research.

[22]  Paul A Meyers,et al.  Osteosarcoma: the addition of muramyl tripeptide to chemotherapy improves overall survival--a report from the Children's Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Shapiro,et al.  The intention-to-treat approach in randomized controlled trials: Are authors saying what they do and doing what they say? , 2007, Clinical trials.

[24]  A. Petrilli,et al.  Results of the Brazilian Osteosarcoma Treatment Group Studies III and IV: prognostic factors and impact on survival. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  S. Baruchel,et al.  Metronomic Dosing of Chemotherapy: Applications in Pediatric Oncology , 2006, Cancer investigation.

[26]  M. Kreuter,et al.  Prognostic relevance of increased angiogenesis in osteosarcoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  R. Kerbel,et al.  Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. , 2003, Cancer research.

[28]  A. Goldhirsch,et al.  Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[29]  Booil Jo,et al.  Statistical power in randomized intervention studies with noncompliance. , 2002, Psychological methods.

[30]  A. Petrilli,et al.  Activity of intraarterial carboplatin as a single agent in the treatment of newly diagnosed extremity osteosarcoma. , 1999, Medical and pediatric oncology.

[31]  Z. Rappaport,et al.  Pediatric brain stem gliomas: an update , 1998, Child's Nervous System.

[32]  A. Lopes,et al.  IIB osteosarcoma. Current management, local control, and survival statistics--São Paulo, Brazil. , 1991, Clinical orthopaedics and related research.

[33]  N. Jaffe,et al.  Increased survival, limb preservation, and prognostic factors for osteosarcoma , 1991, Cancer.

[34]  G. Rosen,et al.  Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. , 1977, Archives of pathology & laboratory medicine.